SMS Pharmaceuticals Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/0fvhwqinbfj62v5wn021yv3h.pdf

Key Takeaways


The Non-ARV Pivot

Potluri: "So what we are considering ARV is as bonus rather than having them having us depend on them."

Ibuprofen: The Volume Bet

Potluri: "So again, so at some point of time, it has to bottom out, right. So we feel that it's more or less almost bottomed out actually at this point in time."

Sitagliptin & the Anti-Diabetic Opportunity


Margins: The Recovery Path

Potluri: "15% to 20% for sure, we can sustain from Q4 onwards. I think we will sustain even earlier. Again, definitely depends on the product mix and suddenly, we get another tender. So that is bonus."

Balance Sheet & Working Capital


JV & VKT Updates


Guidance & Commitments

CommitmentSpecificsTimeline
FY23 revenue growth~10% growth over last year (~₹520–570 crores), despite Q1 weaknessFY23 full year
FY24 revenue growth20% growth, driven primarily by ibuprofen rampFY24
EBITDA margin recovery15–18% rangeFrom Q4 FY23 onwards
Sustainable EBITDA margin15–20%, based on current product profile, excluding ARV upsideFrom Q4 FY23 onwards
Gross margin recovery37–38% rangeFrom Q4 FY23 onwards
Normalized gross margin30–35% range, as focus shifts to high-volume productsOver next two years
Ibuprofen European exportsFirst commercial shipments to European clients post-CEP qualification6–8 months
Sitagliptin US volumesMaterial volume ramp-up when US patent opensLate 2024
VKT facility utilization~80% occupancy, with revenues startingFrom June onwards
CapexNo significant capex; only small environmental spendFY24

Key Metrics

MetricQ2 FY23
Revenue₹159.4 cr, up 148% QoQ; H1 FY23 at ₹223.8 cr
API segment revenue₹159.1 cr, 99.8% of consolidated revenue
EBITDA marginTurned positive in Q2 FY23 after negative in Q1; Q4 FY23 expected at 15–18%
Gross marginPressured by high-cost inventory and pricing; destocking largely complete, normalization expected from Q4 FY23
Profit after taxImpacted by lower API pricing, high-cost inventory, and negative operating leverage
FY23 revenue growth guidance~10% growth from last year, implying ~₹520–570 cr (per an analyst's math)
FY24 revenue growth outlook20% growth projected
Anti-diabetic revenue share~58% of API revenue in Q2 FY23; expected to normalize to 25–30% of topline going forward
ARV revenue share~8% of API revenue, down from 40–50% historically
Ibuprofen capacity utilization~50% of initial installed capacity, or 150 metric tons per month out of 300
Ibuprofen peak revenue potential₹600–700 cr at full capacity utilization with process improvements
Volume growth (YoY)30–35%, driven by ibuprofen ramp-up; revenue degrew 8.7% YoY due to price correction and product mix
Inventory₹261.6 cr total as of Sep 2022; ₹210 cr in WIP and raw materials, ₹50 cr in finished goods
Molnupiravir inventory in WIP~₹50–55 cr, company working to liquidate in ROW markets
Long-term debt₹170 cr; short-term debt ~₹90 cr; average cost of borrowing below 8%
R&D spend~2% of revenue in Q2 FY23; ~3–3.5% in H1 FY23